"Results: A total of 258 NMD [neuromuscular disease] cases following COVID-19 have been reported globally, of which 171 cases were Guillain-Barré syndrome (GBS), 40 Parsonage-Turner syndrome (PTS), 22 Myasthenia Gravis (MG), 19 facial nerve palsy (FNP), 5 single fiber neuropathy, and 1 Tolosa-Hunt syndrome. All (100%) SFN [small fiber neuropathy] patients and 58% of FNP patients were female; in the remaining NMDs, patients were predominantly male, including MG (82%), GBS (63%), and PTS (62.5%). The median time from vaccine to symptom was less than 2 weeks in all groups. Symptoms mainly appeared following the first dose of vector vaccine, but there was no specific pattern for mRNA-based...
Search: We comprehensively searched three databases, Scopus, Medline, and Embase, on 25 January 2023 and updated on 20 February 2023, using a combination of the key terms in multiple domains, including 'COVID-19 vaccine', 'Peripheral neuropathies', 'Cranial neuropathy', 'neuromuscular disease'. Also, we checked the reference lists and citing publications of the included articles for any additional eligible studies ...
Limitaton and strengths: ... To our knowledge, this is the first systematic review of reported cases of COVID-19 vaccine-associated NMD."
© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.